If the Scan Is Clear, — Can You Stop the Tablets?

Your tablet is suppressing cancer cells that are present below the level a scan can detect. A clear scan means the treatment is doing its job — not that there is nothing left to suppress. Most oral targeted therapies and hormone therapies work by maintaining a continuous suppressive effect. When you stop them, that effect stops too. The disease does not stay suppressed on its own simply because the scan looked clear at a point in time.

In most cancers treated with oral therapy, stopping early significantly raises the chance of relapse. When cancer returns after an early stop, it sometimes carries new mutations that make the original treatment less effective when restarted — this is a well-documented risk that NCCN and ASCO factor into treatment duration guidance. If you have already stopped, or are thinking about stopping, tell your team now rather than at your next scheduled appointment. The sooner they know, the more options remain available.

In a small number of blood cancers, formal stopping criteria exist for oral targeted therapy — but these require deep molecular response confirmed across many months of testing, not a scan result, and they apply to specific situations under close monitoring. In most solid tumour treatments, no equivalent criteria currently exist. If you have heard this may be possible for your cancer, ask your oncologist to confirm whether the published criteria apply to your specific stage, treatment and test results before acting on it.

Yes, dose modification is a legitimate and frequently used option, and your oncologist can assess whether it applies to your treatment. The important thing is to raise it directly rather than reducing or stopping on your own. Unplanned changes make it harder for your team to understand what is happening, and supportive medicines alongside the tablet sometimes resolve the problem without any dose reduction at all. Raise it at your next appointment, or sooner if side effects are affecting your daily life.

The decision is based on your treatment protocol — criteria determined by clinical trial evidence and reviewed by NCCN, ASCO and ESMO for your specific cancer type and stage. In some cases there is a fixed duration; in others the decision depends on how the disease has responded over time and what tests show beyond the scan alone. Ask your oncologist to tell you what the planned endpoint of your treatment is and what would change it. A clear answer is reasonable to expect and worth writing down.